Form 4 for ATRA Atara Biotherapeutics, Inc.

Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001140361-22-007765 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-03-03	2022-03-01	ATRA	Dupont Jakob	EVP, Head of R, D	S - Sale	$9.86	-2,221	166.9K	-1%	-$21.9K
D	2022-03-03	2022-03-01	ATRA	Dupont Jakob	EVP, Head of R, D	A - Grant	$0.00	+78.5K	169.1K	+87%	$0
D	2022-03-03	2022-03-01	ATRA	Dupont Jakob	EVP, Head of R, D	A - Grant	$0.00	+147.6K	147.6K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-03-01	S	D	2,221	$9.86	166,879	D	—	—	(F3) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
2	Common	Common Stock	2022-03-01	A	A	78,506	$0.00	169,100	D	—	—	(F1) These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
3	Derivative	Employee Stock Option (Right to Buy)	2022-03-01	A	A	147,573	$0.00	147,573	D	$10.21 · — to 2032-02-28	147,573 Common Stock	(F4) 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.